Expertise and resources to facilitate
Read or watch to learn more
Preclinical characterization of oncology nanomedicines
Expediting nanomedicine development
Protocols

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Nanotechnology Characterization Lab

Eliminating suffering and death from cancer requires an unprecedented collaborative effort that leverages resources from government, industry, and academia. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoparticles.

The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.

There are multiple ways the NCL can help nanotech researchers and developers advance their technology, including characterization, reformulation, optimization, lead selection, method development, and more.

Learn about how to collaborate with the NCL.

News & Updates

The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program.

The NCL has several new brochures that highlight the capabilities, services and resources available through the lab.

Liposomes, colloidial metal nanoparticles, and polymeric/polymeric prodrug nanoparticles are among the most common nanotechnology platforms used in drug delivery.

The NCL is temporarily opening its Assay Cascade characterization program to nanotech concepts with a focus on COVID-19.

Meet Us @

There will be a virtual conference on the Advances and Challeges in Nanomedicine, April 12-13, 2021. Dr.

For those who were unable to attend the live sessions of recent CLINAM conference, the recordings have been posted on YouTube.

This is a pre-recorded webinar presented by Dr. Stephan T. Stern, in partnership with One Million Solutions in Health.

This is a pre-recorded webinar presented by Dr. Stephan T. Stern, in partnership with One Million Solutions in Health.